A retrospective study on clinical efficacy and safety of adjunctive therapy for knee osteoarthritis with the treatment of buprenorphine transdermal patches, diprospan and celebrex

A retrospective study on clinical efficacy and safety of adjunctive therapy for knee osteoarthritis with the treatment of buprenorphine transdermal patches, diprospan and celebrex.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800014977

Enrollment

Unknown

Registered

2018-02-26

Start date

2018-03-31

Completion date

Unknown

Last updated

2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

A:Physicotherapeutics add Celebrex

B:Physicotherapeutics + Diprospan

C:Physicotherapeutics + Buprenorphine Transdermal Patches

D:Physicotherapeutics

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: 40-60 years old; No serious cardiovascular, cerebrovascularand hematopoietic diseases; Liver, kidney and lung function normally; Roughly normal bloos pressure and blood sugar; Non operation history of knee; Signed informed consent; Knee pain on most days of the week; Less than 30 minutes of morning stiffness Bony enlargement; Bony tenderness to palpation; Signs of inflammation; Radiographic evidence of OA or meets clinical criteria for knee OA.

Exclusion criteria

Exclusion criteria: No accord with age standard; No signed informed consent; Diagnosis of rheumatoid arthritis, fibromyalgia, inflammation of infrapatellar fat pad, corpus liberum, or other systemic rheumatic disease; Hospitalized for a stroke, myocardial infarction or coronary artery revascularization in the past 3 months; Active diagnosis of psychosis or serious personality disorder; Severely impaired hearing or speech (patients must be able to respond to phone calls); Unable to speak Chinese; No access to a telephone; Participating in another OA intervention or other lifestyle change study; Dementia or other memory loss condition; Current, uncontrolled substance abuse disorder; Motor neuron diseases, Parkinson's Disease, multiple sclerosis; Quadriplegic or paraplegic; Serious / terminal illness as indicated by referral to hospice or palliative care; Other self-reported health problem that would prohibit participation in the study; Other health conditions or personal issues judged by a study team member or primary care physician to make the patient inappropriate for the study; Metastatic Cancer; History of gout in knee or hip; Total joint replacement (knee or hip) surgery, other knee or hip surgery, meniscus tear (verified by MRI), or ligament (ACL, PCL, MCL and LCL) tear.

Design outcomes

Primary

Measure	Time frame
VAS score;Lysholm score;	—

Secondary

Measure	Time frame
Adverse events;	—

Countries

China

Contacts

Public ContactLiu Baorong

Hunan Province People's hospital

lbr9391@163.com+86 13787119391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026